News
A Phase 1, First-in-Human Study of CT-95, a Mesothelin-Directed Bispecific T Cell Engager (TCE) in Subjects with Advanced Solid Tumors
Rodriguez Rivera et al.
Society for Immunotherapy of Cancer (SITC) I Annual Meeting I Abstract 536 I November 7-9, 2025
Determination of first in human dose of the T cell-redirecting bispecific antibody CT-95 targeting mesothelin and CD3
Stanley Roberts, Kelly Byrnes-Blake, and Eric Butz
American Association for Cancer Research I Annual Meeting I Abstract 4884 I April 26-30, 2025